While it is not clear how this variability in in-vitro responses will translate to patient-to-patient variance in therapeutic response, several groups have reported concordance between in-vitro responses to CFTR modulators and CF patient specific clinical responses [42–45]. Here, CFTR is linked to cystic fibrosis.